Prothena partner Novo Nordisk to advance coramitug to Phase 3 for ATTR-CM

PROTHENA CORP PUBLIC LTD CO

Novo Nordisk plans Phase 3 program for coramitug in ATTR-CM, start expected in 2025.
Prothena eligible for up to $1.2B in milestones, $100M received to date.
Clinical milestone payment triggered when prespecified enrollment criteria met in Phase 3.
Coramitug is a potential first-in-class amyloid depleter antibody.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.